Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Clinical relevance of geriatric assessment

Raúl Córdoba • 22 Jun 2020
EHA 2020
General

Raul Cordoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, outlines the clinical relevance of geriatric assessment in older patients with hematological malignancies and studies evaluating this. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raúl Córdoba

The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies
1:30
The pharmacometrics of odronextamab in R/R FL & DLBCL based on the ELM-1 & 2 studies
Raúl Córdoba • 15 Jun 2024
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2
1:11
Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2
Raúl Córdoba • 15 Jun 2024
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
1:27
Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
Raúl Córdoba • 15 Jun 2024
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
2:03
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
Raúl Córdoba • 7 Oct 2023

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals